Nav: Home

'Epigenetic' drug may boost success of parp inhibitor treatment for leukemias and breast cancers

October 10, 2016

Drugs called PARP inhibitors, which sabotage cancer cells' ability to repair damage to their DNA, have shown some promise in treating human breast cancers that contain BRCA1 and BRCA2 gene mutations. Now, a new study in lab-grown cancer cells and mice suggests that their effectiveness could be strengthened and expanded to other forms of breast cancer and leukemia not linked to BRCA mutations by adding a so-called epigenetic drug.

A team of researchers at the Johns Hopkins Kimmel Cancer Center and the University of Maryland Greenebaum Comprehensive Cancer Center report that a combination of an experimental and not-yet-approved PARP inhibitor called talazoparib and an epigenetic drug called 5-azacytidine, approved for a pre-leukemic disorder called myelodysplasia, resulted in a strong antitumor response against breast cancer cells without BRCA mutations and in halting the growth of acute myeloid leukemia cells.

Between 25 and 28 days after the start of the combination treatment, human breast tumors grown in mice measured about half the volume of tumors treated with either drug alone, the team says.

In another set of experiments in which human leukemia cells were transplanted into mice, at 16 and 30 days after the start of the combination treatment, leukemia volumes in the mice were at least half as small as tumors treated with either drug alone.

The findings, described Oct. 10 in Cancer Cell, are the result of a collaboration between a team led by Stephen B. Baylin, M.D., co-director of the Cancer Biology Program at the Kimmel Cancer Center, and his wife, Feyruz V. Rassool, Ph.D., of the University of Maryland School of Medicine.

It was "somewhat of a surprise that leukemia cells were this sensitive to the combination treatment," says Baylin, "and if further research confirms our findings, it looks like it also could be useful for breast cancer and ovarian cancers for which PARP inhibitors have not been useful as yet."

PARP inhibitors work by blocking the poly (ADP-ribose) polymerase enzyme or PARP, which helps repair naturally occurring breaks in strands of DNA. Some cancers rely more frequently on PARP than others, Baylin says, and for tumors sensitive in that way, the inhibitors are one clinical weapon in sabotaging the cancer cells' ability to repair their own DNA.

Baylin adds that PARP inhibitors also "work according to how intensely and durably the PARP enzyme is trapped at certain DNA damage sites." Thus, he says, "If you can ramp up the duration and intensity of this trapping, you could potentially increase the efficacy of the drug."

The research team found that the combination of 5-azacytidine and talazoparib increased the time that PARP was trapped at sites of DNA damage in cancer cells, extending the time from 30 minutes to three to six hours after treatment.

Although talazoparib, which is being developed by Medivation Inc., is not yet approved by the Food and Drug Administration, another PARP inhibitor called olaparib is approved for patients with advanced ovarian cancer and BRCA mutations. Scientists are searching for ways to expand and improve the use and effectiveness of PARP inhibitors, Baylin says.

Epigenetic drugs work by changing the property of DNA -- how it's coiled and processed. Specifically, 5-azacytidine blocks proteins that attach gene-regulating methyl groups to DNA and traps those proteins on DNA. The proteins blocked by 5-azacytidine also interact with PARP enzymes at DNA damage sites, explains Baylin. "We figured that if we pair 5-azacytidine and a PARP inhibitor like talazoparib, we may be able to increase PARP trapping at DNA damage sites," says Baylin.

Baylin says plans to test the combination therapy in a clinical trial for patients with advanced acute myeloid leukemia are pending at the University of Maryland. "Advanced leukemia is a tough disease to treat, and we urgently want to give patients more options," Baylin says. "Hopefully, success in this trial will also spur subsequent clinical trials for other tumor types like breast cancer and ovarian cancer without BRCA mutations."
Baylin and Rassool are members of a Stand Up To Cancer team -- which Baylin co-leads with Peter Jones, Ph.D., at the Van Andel Research Institute -- which aims to develop epigenetic therapy for patients with cancer.

Other scientists who contributed to the research include Kimmel Cancer Center researchers Limin Xia and Yi Cai; Nidal E. Muvarak, Khadiza Chowdhury, Carine Robert, Pratik Nagaria, Søren M. Bentzen, Eun Yong Choi, Vu H. Duong, Maria R. Baer, Rena G. Lapidus, Ying Zou and Zeba N. Singh of the University of Maryland School of Medicine; Marina Bellani and Michael M. Seidman of the National Institute on Aging; and Tyler Rutherford of Stevenson University.

Robert, Rassool and Baylin share co-inventorship on U.S. Provisional Patent Application No. 61/929,680 for the concept of the combinatorial therapy.

Baylin and Rassool say they began this research after they were awarded a prize in 2012 from the Entertainment Industry Foundation and Stand Up To Cancer (SU2C), named for the late film producer Laura Ziskin, who died of breast cancer. Other funding was provided by the Van Andel-Research Institute-SU2C Epigenetics Dream Team, the Adelson Medical Research Foundation, Maryland Cigarette Restitution funds, the Leukemia Lymphoma Society and the National Institute on Aging (Z01 AG000746-08).

Johns Hopkins Medicine

Related Breast Cancer Articles:

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.
Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.
More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.
Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.
Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.
Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.
Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.
Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.
Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
Blood test offers improved breast cancer detection tool to reduce use of breast biopsy
A Clinical Breast Cancer study demonstrates Videssa Breast can inform better next steps after abnormal mammogram results and potentially reduce biopsies up to 67 percent.
More Breast Cancer News and Breast Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.